---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Mechanism of action"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Mechanism of action. Topics: Combination: company description of the target and the two components; Combination: noradrenergic excitation and antimuscarinic disinhibition of the hypoglossal motor nucleus; Combination: proposed mechanism by which aroxybutynin offsets the wake-promoting effect of atomoxetine, not yet shown in animal models; Aroxybutynin: the R-enantiomer of racemic oxybutynin; 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Combination: company description of the target and the two components

> “Oxnimbi is a combination of aroxybutynin and atomoxetine designed to target the neuromuscular defect of OSA and improve upper airway muscle activity during sleep.”
> “Aroxybutynin is a type of anticholinergic agent that blocks the activity of the muscarinic acetylcholine receptor”
> “The selection of atomoxetine is to promote adrenergic tone leading to muscle activation.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.1-2"></a>

### Combination: noradrenergic excitation and antimuscarinic disinhibition of the hypoglossal motor nucleus

> “AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.”
> “Atomoxetine, a selective norepinephrine reuptake inhibitor, was expected to increase synaptic norepinephrine and enhance central excitatory drive to upper airway motor neurons, thereby improving dilator muscle tone. Aroxybutynin, a selective antimuscarinic agent, was hypothesized to reduce muscarinic inhibition of HMN activity (Figures 1 and 2). Together, this dual mechanism was designed to stabilize upper airway muscle activation across NREM and REM sleep and mitigate sleep-related relaxation of the airway.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.1-3"></a>

### Combination: proposed mechanism by which aroxybutynin offsets the wake-promoting effect of atomoxetine, not yet shown in animal models

> “Thus, when combined, a significant potential benefit of aroxybutynin and atomoxetine is the overall stabilization of sleep through the mitigation of the wake-promoting activity caused by atomoxetine.”
> “Since atomoxetine administration promotes wakefulness alongside an increase in cortical acetylcholine levels, we have hypothesized that the attenuation of this wake-promoting effect by co-administration of aroxybutynin is due to the blockade of atomoxetine-evoked cholinergic stimulation of the cortex. In this scenario, aroxybutynin would block atomoxetine-mediated activation of a critical arousing pathway while importantly preserving the α1-receptor-dependent activation of upper airway motor pathways. Although this theoretical mechanism has not yet been proven in animal models, we believe it represents a plausible explanation for the unique effects observed when combining these two compounds on OSA severity, upper airway muscle activity and sleep continuity.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.1-4"></a>

### Aroxybutynin: the R-enantiomer of racemic oxybutynin

> “Aroxybutynin (also known as R-oxybutynin) is a novel drug that, to our knowledge, has not previously been marketed or approved by the FDA or any other regulatory agency, for any indication.”
> “Oxybutynin is composed of an equal mixture of aroxybutynin and S-oxybutynin, i.e., it is a racemic mixture.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 refined the original combination by substituting oxybutynin with aroxybutynin, the R-enantiomer that mediates most of oxybutynin’s antimuscarinic actions.”
> “Concentrating the pharmacologic activity in a single active stereoisomer allows for equivalent effects on the upper airway at a lower total dose, with the potential for fewer off-target effects and better overall tolerability.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.1-5"></a>

### Oxybutynin label: muscarinic antagonism residing predominantly in the R-isomer

> “Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle.”
> “Antimuscarinic activity resides predominantly in the R-isomer.”
> “A metabolite, desethyloxybutynin, has pharmacological activity similar to that of oxybutynin in in vitro studies.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.6.1-6"></a>

### Atomoxetine label: selective inhibition of the presynaptic norepinephrine transporter

> “Atomoxetine is a selective norepinephrine reuptake inhibitor.”
> “The precise mechanism by which STRATTERA produces its therapeutic effects in ADHD is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.”
> “4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
